Bulk Deal: 3 Stocks in Focus After Prominent Investor Buys and Sells Stake in Companies

Synopsis:- Several stocks remained in focus after bulk deals involving stakes like 2.57%, 0.9%, and 0.94%, with transactions exceeding ₹26 crore and ₹19 crore. Prices hovered around ₹115–₹1,800, reflecting active participation, shifting ownership trends, and evolving investor sentiment in the market.

A bulk deal is a large share transaction executed on a stock exchange, usually involving institutional investors. These trades exceed a specified volume threshold and must be publicly disclosed, helping market participants track changes in ownership, investor sentiment, and the level of confidence investors have in a particular stock.

Rajputana Stainless

Rajputana Stainless Ltd is engaged in the manufacturing and processing of stainless steel products, catering to industries such as construction, engineering, and consumer goods. The company focuses on quality production and expanding its product portfolio. With growing demand for stainless steel, it aims to strengthen its market presence and scale operations efficiently.

With a market capitalisation of Rs 966.46 crore, the shares were trading at Rs 115.65 per share, increasing around 2.44 percent as compared to the previous closing price.

According to exchange data, Craft Emerging Market Fund, via its Citadel and Elite Capital funds, acquired a combined 21.5 lakh shares of Rajputana Stainless, representing a 2.57 percent stake, at an average price of ₹122 per share. This investment, totalling over ₹26 crore, reflects growing institutional interest and confidence in the company’s outlook.

Additionally, other investors also participated actively, with Sapan Anil Shah HUF buying 5.3 lakh shares for ₹6.3 crore and Smital Suresh Thakkar acquiring 5.4 lakh shares worth ₹6.58 crore. Therefore, the combined buying across institutional and individual investors signals strong accumulation trends and positive market sentiment.

Bliss GVS Pharma

Bliss GVS Pharma Ltd is a pharmaceutical company specialising in the development and manufacturing of formulations, particularly in suppositories and pessaries. It has a strong presence in international markets, especially in emerging economies. The company focuses on affordable healthcare solutions, leveraging its niche expertise and global distribution network for sustained growth.

With a market capitalisation of Rs 2,233 crore, the shares were trading at Rs 211 per share, increasing around 1.83 percent as compared to the previous closing price.

According to NSE data, Bliss GVS Pharma witnessed notable stake reshuffling as Mateus acquired 9.33 lakh shares, representing a 0.9 percent stake, at ₹210.81 per share for ₹19.68 crore. Meanwhile, Arian Investment exited 10 lakh shares (0.94 percent stake) at ₹210.82 per share for ₹21.08 crore. As of December 2025, Mateus held 2.42 percent, whereas Arian Investment owned 4.72 percent, indicating a partial shift in institutional ownership.

ICICI Lombard General Insurance Company Ltd

ICICI Lombard General Insurance Company Ltd is one of India’s leading private sector general insurers, offering a wide range of products including motor, health, travel, and corporate insurance. Backed by strong brand presence and digital capabilities, the company focuses on innovation, risk management, and customer-centric solutions to drive consistent growth.

With a market capitalisation of Rs 90,124 crore, the shares were trading at Rs 1,808 per share, increasing around 0.99 percent as compared to the previous closing price.

ICICI Lombard has made a strategic investment in HDFC Bank, which has a market capitalization of ₹12.31 trillion. The company acquired shares worth approximately ₹0.39 billion in multiple tranches, taking its total holding to around 0.05% as of March 19, 2026. The transaction is at arm’s length and not a related party deal.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Bulk Deal: 3 Stocks in Focus After Prominent Investor Buys and Sells Stake in Companies appeared first on Trade Brains.